PARP inhibitors are a promising alternative to chemotherapy for patients with metastatic BRCA1 and BRCA2 breast cancer
PARP inhibitors are a promising alternative to chemotherapy for patients with metastatic BRCA1 and BRCA2 breast cancer
Ribociclib and endocrine therapy improves survival for pre-menopausal women with advanced breast cancer
Comment: The use of CDK 4/6 inhibitors now translates to a significant survival benefit in breast cancer treatment
Exercise: How it can help both during and after cancer treatment
Treating bladder problems for ovarian cancer patients
The importance of exercising throughout cancer treatment
Bladder Problems following ovarian cancer treatment
Cardiac events following radical radiotherapy for lung cancer
Highlights from IGILUC 2019
Quality of life and local treatment of oligometastatic prostate cancer
Digitising clinical assessment and using it for evidence-based prediction of outcomes
Ethics of cancer care: Beyond biology and medicine